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CASE REPORT
Recurrent autoimmune hemolytic anemia in splenic marginal zone lymphoma
Oreoluwa Oladiran, Rashmi Dhital and Anthony Donato
Internal Medicine, Reading Hospital, Tower Health System, PA, USA
ABSTRACT
Autoimmune hemolytic anemia (AIHA) is a condition associated with an extensive differential
diagnosis that includes lymphoid malignancies. Although AIHA occurs in about 10–25% of
patients with chronic lymphocytic leukemia, it is also reported to occur in all of the other
lymphoid subtypes. In this article, we report a case of recurrent AIHA in a 67-year-old woman
with two acute episodes of hemolysis separated by 3 years of hematologic remission. Both
episodes were severe enough to require blood transfusion, oral steroids, and rituximab. Bone
marrow biopsy and immunophenotyping using flow cytometry done during both admissions
confirmed the presence of splenic marginal zone lymphoma.
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1. Case report
A 67-year-old woman presented to the emergency
room with a 2-month history of generalized weakness,
fatigue, night sweats, intermittent fever, and uninten-
tional 9-kg weight loss. Three years prior to presenta-
tion, she reported similar symptoms and was
diagnosed with autoimmune hemolytic anemia
(AIHA) secondary to splenic marginal zone lym-
phoma (SMZL), managed with oral steroids and
seven doses of rituximab leading to clinical remission.
Vital signs on this presentation were within nor-
mal limits, including normal oxygen saturation of
96% on ambient air. Physical examination revealed
conjunctival pallor, scleral icterus, and bilateral axil-
lary lymphadenopathy. Abdominal examination was
notable for mild splenomegaly.
Laboratory tests showed hemoglobin count of
6.3 g/dL (12–16 g/dL) with mean corpuscular volume
107.7 fL (80–99 fL), reticulocyte count 18.8% (0.5–
2.0%), lactate dehydrogenase level 270 U/L (100–
225 U/L), haptoglobin level <30 mg/dL (44–215 mg/
dL), and total bilirubin level 3.8 mg/dL (0.2–1.3 mg/
dL) with Coombs test positive for antibodies detected
on her red blood cells. Peripheral blood smear
showed reticulocytosis and minimal spherocytosis
with hypochromic cells. Platelet count, basic meta-
bolic panel, iron studies, folate level, and vitamin B12
level were all within normal limits. Hepatitis C serol-
ogy was negative. CT scan of the abdomen identified
splenomegaly along with a partially calcified mass
within the anterior spleen. Repeat bone marrow
biopsy was performed, and histology revealed the
presence of low-grade B-cell lymphoma. Peripheral
blood immunohistochemistry analysis identified cells
with CD19, CD20, and FMC7 but negative for CD3,
CD5, and CD103.
She was initially transfused with packed red cells,
and 80 mg oral prednisone daily was commenced
with folic acid supplementation. Her hemoglobin
count improved from 6.2 g/dL on admission to
8.4 g/dL on day 3. She responded promptly and was
discharged on tapered steroid dose. She completed
her course of oral steroid on the tenth day post-
discharge and was followed up in the hematology
clinic with regular monitoring of her hemoglobin.
After about 3 months, a routine complete blood
count (CBC) showed hemoglobin count of 7 g/dL,
down from 11 g/dL the preceding month. This time,
she was placed on oral prednisone 60 mg to taper and
weekly rituximab for 4 weeks and thereafter main-
tained on rituximab every two months planned for
the next 2 years, with close monitoring of CBC for
early detection of recurrence.
2. Discussion
Autoimmune hemolytic anemia (AIHA) is a disorder
that affects 0.017% of the general population [1]. It is
caused by antibody production against red blood cell
antigens, resulting in shortened red cell survival.
AIHA can be idiopathic or secondary and character-
ized as warm, cold, or mixed types based on the
thermal range of the antibody activity. Warm AIHA
comprises 80–90% of all AIHA cases. It is mediated
mostly by immunoglobulin G and is associated with
connective tissue diseases, viral exposures, and malig-
nancies including lymphomas [2].
Splenic marginal zone lymphoma (SMZL) is a
rare type of non-Hodgkin lymphoma (NHL),
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accounting for approximately 1% of total B-cell
NHL [3], and was believed to be the cause of recur-
rent AIHA in this case. In case series of SMZL
patients, approximately 25% were documented to
have some autoimmune disorders, most commonly
autoimmune cytopenias, which are sometimes the
presenting feature of the disease [4,5]. As described
in our case, symptoms of AIHA may be nonspecific,
including fatigue, intermittent fever, and weight
loss. Splenomegaly is usually present due to chronic
extravascular hemolysis. Markers of red cell hemo-
lysis are usually present including decreased serum
haptoglobin, elevated lactate dehydrogenase, and
increased serum bilirubin. In cases of antibody-dri-
ven extravascular hemolysis, spherocytosis is pre-
sent, as was in our patient.
Based on evidence of acute antibody-mediated hemo-
lytic anemia and given the patient’s history of SMZL, our
top suspicion was a recurrence of her low-grade B-cell
lymphoma. We also considered the possibility of other
lymphoid malignancies. Chronic lymphocytic leukemia
was excluded based on absence of lymphocytosis and
negative CD38 on flow cytometry. Other T-cell markers
were also absent on immunohistochemistry, essentially
ruling out other T-cell lymphomas. Hodgkin lymphoma
was excluded by the absence of Reed–Sternberg cells on
bonemarrow histology and by flow cytometry. Although
genetic testing for NOTCH2 and TP53 was not done in
our patient, studies have shown that these genemutations
are independent markers of poor prognosis [6]
Most patients respond to oral steroids, but only
about 15–20% will undergo complete remission with-
out requiring maintenance doses [7]. Steroid-resistant
patients are treated with anti-CD20 therapies such as
rituximab. Rituximab monotherapy is effective in
SMZL with results similar to splenectomy and with-
out the resultant post-splenectomy complications
[8,9]. Studies comparing the overall survival of
patients with SMZL treated with splenectomy and
rituximab did not show any advantage of splenect-
omy over rituximab. Currently, no guidelines exist
for splenectomy in SMZL patients, however, it can
be considered in patients with bulky splenomegaly
and cytopenias without extensive bone marrow infil-
tration or in patients with repeated failed rituximab
treatments [10]. Management approach should be
based on the extent of the disease and individual
patient characteristics.
Studies have also shown that the presence of AIHA in
patients with SMZL confers poor prognosis and serves as
a marker of disease activity [11] hence the need to con-
sider this during risk stratification of patients.
Learning points
● Although uncommon, recurrent autoimmune
hemolytic anemia from SMZL does occur, some-
times being the harbinger of relapse.
● Rituximab remains the preferred treatment option
in steroid-resistant patients with SMZL except in
certain circumstances.
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